Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Rare Diseases

Lung Neoplasms

Carcinoma

Small Cell Lung Carcinoma

Carcinoma, Neuroendocrine

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Small Cell Lung Cancer

Neuroendocrine Tumor

Neuroepithelioma

DLL3-Directed Chimeric Antigen Receptor T-cells (CAR T)

DLL3 directed autologous Chimeric Antigen Receptor T-cells

LB2102

Legend Biotech USA

Tina Swartzlander

Alberto Chiappori, MD

Zhonglin Hao, MD

Heather L Heath

Hope Wei, BA

Jordan Weiss, BA

Jacob Sands, MD

Adam Schoenfeld, MD

Sophie Hieronymi

This is a phase 1, first-in-human, open-label, multicenter, dose escalation and expansion study of DLL3-targeted chimeric antigen receptor T-cells in subjects with extensive stage small cell lung cancer or large cell neuroendocrine lung cancer.

This is a phase 1, first-in-human, open-label, multicenter, dose escalation and expansion study of DLL3-targeted chimeric antigen receptor T-cells in subjects with extensive stage small cell lung cancer or large cell neuroendocrine lung cancer. The study comprises a dose-escalation component (Part A) and a cohort expansion component (Part B). Up to 41 subjects will be treated in this study. Part A will enroll and treat up to 24 subjects and Part B will be conducted after the recommended dose for expansion (RDE) has been identified in Part A and enroll up to 17 subjects. Both parts of this trial will include a Screening Period, a Pretreatment Period, a Treatment Period, a Follow-Up Period, and a Post-Progression Follow-Up Period.

DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

A First in Human Dose Escalation and Cohort Expansion Study of DLL3-directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

Multiple doses will be tested to establish a recommended dose

Treatment of additional patients at the recommended dose as identified in the initial dose escalation part of the study

Measured by Response Evaluation Criteria In Solid Tumors (RECIST)

CAR-positive T cell counts in cells/microliter (μL) blood

Number of subjects with presence of anti-LB2102 antibodies

Legend Biotech USA Inc

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer	NCT05680922	Small Cell Lung... Large Cell Neur...	LB2102	18 Years -	Legend Biotech USA Inc
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer	NCT05680922	Small Cell Lung... Large Cell Neur...	LB2102	18 Years -	Legend Biotech USA Inc
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer	NCT05680922	Small Cell Lung... Large Cell Neur...	LB2102	18 Years -	Legend Biotech USA Inc

Spots Global Cancer Trial Database for lb2102

Every month we try and update this database with for lb2102 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for lb2102

Every month we try and update this database with for lb2102 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for lb2102 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.